Monocyte chemotactic protein-1 (MCP1) and the PTH anabolic effect in bone.

趋化因子及其受体是许多组织中细胞-细胞相互作用的主要调节因子。该项目探讨单核细胞趋化蛋白-1 （MCP1或CCL2）在骨中的强烈增加，在治疗中甲状旁腺激素（钙稳态的控制器）用于增加骨量以预防骨质疏松症。MCP1先前被认为是一种炎症调节剂，在感染期间被诱导，在自身免疫性疾病中很重要，因此它在骨骼中的作用是非常出乎意料的。

Chemokines and their receptors are major regulators of cell-cell interactions in many tissues. This project explores the strong increase of monocyte chemotactic protein-1 (MCP1 or CCL2) in bone, in a treatment where parathyroid hormone (a controller of calcium homeostasis) is used to increase bone mass to prevent osteoporosis. MCP1 was previously thought to be an inflammatory regulator, induced during infection and important in autoimmune conditions, so its role in bone was highly unexpected.